Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1780Triple Negative Breast Neoplasms 299Ovarian Neoplasms 136Lung Neoplasms 115Colorectal Neoplasms 115Neoplasms 106Prostatic Neoplasms 103Carcinoma, Non-Small-Cell Lung 101Neoplasm Metastasis 96Stomach Neoplasms 81Pancreatic Neoplasms 78Melanoma 74Endometrial Neoplasms 65Head and Neck Neoplasms 60Uterine Cervical Neoplasms 56Squamous Cell Carcinoma of Head and Neck 50Colonic Neoplasms 45Esophageal Neoplasms 42Sarcoma 41Carcinoma, Intraductal, Noninfiltrating 41Motor Activity 37HER2-positive Breast Cancer 34Urinary Bladder Neoplasms 33Liver Neoplasms 31Carcinoma, Renal Cell 30Brain Neoplasms 28Advanced Breast Cancer 25Lymphedema 24Kidney Neoplasms 24Carcinoma, Transitional Cell 23

Interventions

eribulin 1disitamab vedotin 1RC48 antibody 1Paclitaxel 1Gemcitabine 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × HER2-low Breast Cancer × Breast × Clear all
NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
37 enrolled
Breast

HER2-low Breast Cancer

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡